[go: up one dir, main page]

AR090439A1 - Lipopeptidos antimicrobianos cortos - Google Patents

Lipopeptidos antimicrobianos cortos

Info

Publication number
AR090439A1
AR090439A1 ARP130100903A ARP130100903A AR090439A1 AR 090439 A1 AR090439 A1 AR 090439A1 AR P130100903 A ARP130100903 A AR P130100903A AR P130100903 A ARP130100903 A AR P130100903A AR 090439 A1 AR090439 A1 AR 090439A1
Authority
AR
Argentina
Prior art keywords
peptides
proline
lipid
acid
lysine
Prior art date
Application number
ARP130100903A
Other languages
English (en)
Inventor
Carmichael Robin
Zhang Lijuan
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Publication of AR090439A1 publication Critical patent/AR090439A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Péptidos que presentan actividad biológica y terapéutica, que en particular, son dipéptidos o tripéptidos lipidados que son análogos de los péptidos KPV y KdPT y que presentan actividad antimicrobiana. Más precisamente, los péptidos presentan una actividad antimicrobiana que es superior a la de los tripéptidos originales lisina-prolina-valina y lisina-d-prolina-tirosina. Los péptidos que se describen presentan la fórmula general lípido C₁₂₋₁₈-KXZ-NH₂, donde K es lisina, X es prolina, d-prolina, histidina o arginina, Z es opcional, y si está presente, es valina, treonina, alanina o leucina, y el grupo COOH en el extremo está amidado con NH₂. El lípido C₁₂₋₁₈ preferiblemente es una unidad lipídica que se selecciona entre el ácido láurico (C₁₂), el ácido mirístico (C₁₄), el ácido pentadecanoico (C₁₅), el ácido palmítico (C₁₆) y el ácido esteárico (C₁₈). Métodos para usar estos péptidos en el tratamiento de diversas lesiones, inflamaciones o infecciones que son provocadas por bacterias en la piel o en otras superficies mucosas del cuerpo, como es el caso de la cavidad oral. Composición farmacéutica.
ARP130100903A 2012-03-20 2013-03-20 Lipopeptidos antimicrobianos cortos AR090439A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261613212P 2012-03-20 2012-03-20

Publications (1)

Publication Number Publication Date
AR090439A1 true AR090439A1 (es) 2014-11-12

Family

ID=47901428

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100903A AR090439A1 (es) 2012-03-20 2013-03-20 Lipopeptidos antimicrobianos cortos

Country Status (19)

Country Link
US (1) US9278994B2 (es)
EP (1) EP2827907B1 (es)
JP (1) JP6261560B2 (es)
KR (1) KR20140136494A (es)
CN (2) CN104379177B (es)
AR (1) AR090439A1 (es)
AU (1) AU2013235692B2 (es)
CA (1) CA2864179A1 (es)
DK (1) DK2827907T3 (es)
ES (1) ES2729237T3 (es)
HK (1) HK1204453A1 (es)
MX (1) MX2014011290A (es)
MY (1) MY163100A (es)
PL (1) PL2827907T3 (es)
RU (2) RU2017127273A (es)
SG (2) SG10201607784VA (es)
TW (1) TWI541254B (es)
WO (1) WO2013142088A1 (es)
ZA (1) ZA201405950B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6906274B2 (ja) * 2014-06-30 2021-07-21 ロート製薬株式会社 外用組成物、眼科用組成物、抗菌剤、及び抗菌方法
US10835572B2 (en) 2014-06-30 2020-11-17 Rohto Pharmaceutical Co., Ltd. Composition for external application
US10660979B2 (en) * 2015-08-26 2020-05-26 The General Hospital Corporation System and method for electrical control of bacteria
KR101855170B1 (ko) 2015-11-18 2018-05-08 (주)노바셀테크놀로지 신규 항균 펩타이드 및 그의 용도
CN109320585B (zh) * 2018-09-06 2021-10-26 南方医科大学 一种具有专一性抗痤疮丙酸杆菌作用及抗炎作用的短脂肽
US20220257569A1 (en) * 2018-09-12 2022-08-18 The Governing Council Of The University Of Toronto Indole-oxadiazole compounds and their therapeutic use
CN111035764B (zh) * 2018-10-14 2021-09-07 深圳市健元医药科技有限公司 一种治疗类风湿性关节炎的组合物及其制备方法
CN110279844A (zh) * 2019-01-31 2019-09-27 浙江星杭泰乐生物医药有限公司 人工合成抗菌肽在制备抑菌消炎祛痘化妆品或外用药物制剂中的应用及抑菌消炎祛痘组合物
CN111303242B (zh) * 2020-02-27 2022-04-26 广州领晟医疗科技有限公司 一种KdPT的修饰肽
KR102163568B1 (ko) * 2020-08-21 2020-10-07 주식회사 비드테크 지방산 항균펩타이드 및 이를 함유하는 항균 조성물
EP4221673A1 (en) * 2020-09-29 2023-08-09 Unilever IP Holdings B.V. A personal care composition comprising amino acids
US11793746B2 (en) * 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
CN112679576B (zh) * 2020-11-06 2022-09-20 黄石瀚海新材料科技有限公司 抗菌脂肽、抗菌脂肽水凝胶制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614369B1 (en) * 1991-10-28 1999-12-29 Cytran Ltd. Pharmaceutical dipeptide compositions and methods of use thereof
JP3273314B2 (ja) * 1998-08-12 2002-04-08 独立行政法人農業生物資源研究所 抗菌ペプチド及びこれを有効成分とする抗菌剤
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
AU2004246909B2 (en) * 2003-06-19 2010-08-19 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
EP1686957B1 (en) * 2003-11-17 2012-03-07 Sederma Compositions containing mixtures of tetrapeptides and tripeptides
FR2870244B1 (fr) * 2004-05-11 2011-01-07 Centre Nat Rech Scient Conjugues dipeptidiques antagonistes de l'alpha-msh
DE102004055541A1 (de) 2004-11-17 2006-05-18 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
CN102329375A (zh) * 2011-09-30 2012-01-25 中国药科大学 一组末端酰胺化的抗菌肽

Also Published As

Publication number Publication date
CN107080831A (zh) 2017-08-22
EP2827907A1 (en) 2015-01-28
MY163100A (en) 2017-08-04
AU2013235692A1 (en) 2014-09-25
AU2013235692B2 (en) 2016-12-08
JP2015512386A (ja) 2015-04-27
JP6261560B2 (ja) 2018-01-17
CN104379177B (zh) 2017-07-04
HK1204453A1 (en) 2015-11-20
US9278994B2 (en) 2016-03-08
CN104379177A (zh) 2015-02-25
US20150080291A1 (en) 2015-03-19
RU2014142038A (ru) 2016-05-10
RU2627648C2 (ru) 2017-08-09
TW201339176A (zh) 2013-10-01
EP2827907B1 (en) 2019-03-06
WO2013142088A1 (en) 2013-09-26
ZA201405950B (en) 2017-08-30
KR20140136494A (ko) 2014-11-28
SG10201607784VA (en) 2016-11-29
CA2864179A1 (en) 2013-09-26
MX2014011290A (es) 2014-10-13
RU2017127273A (ru) 2019-02-04
DK2827907T3 (da) 2019-06-11
PL2827907T3 (pl) 2019-08-30
SG11201405244RA (en) 2014-10-30
TWI541254B (zh) 2016-07-11
ES2729237T3 (es) 2019-10-31

Similar Documents

Publication Publication Date Title
AR090439A1 (es) Lipopeptidos antimicrobianos cortos
ES2572260T3 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas
MX2012002216A (es) Nueva endolisina obpgplys.
CO2021014694A2 (es) Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio
UY33047A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
MX2009009022A (es) Vacunas de peptídicas para cánceres que expresan antígenos asociados con tumores.
DOP2012000265A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.
AR078374A1 (es) Peptidos aislados de veneno de arana y sus usos como potentes y selectivos bloqueadores del canal ionico
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
PE20091007A1 (es) Depsipeptidos ciclicos como moduladores de calicreina 7
BR112014021653A2 (pt) Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica
MX2019005979A (es) Peptidos modificados.
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
CL2011001363A1 (es) Proceso para la preparacion de un compuesto derivado de etorfina; compuesto derivado de etorfina; composicion farmaceutica que lo comprende; uso del compuesto como analgesico en el tratamiento del dolor.
BR112016026637A2 (pt) associação de um tetrapeptídeo e um gliceril éster para tratamento de alopecia androgênica
BR112013024265A2 (pt) peptídeo cíclico, uso de peptídeos cíclicos, método para o tratamento de doenças, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica
EA201892320A1 (ru) Способ лечения или предупреждения остеоартрита
BR112018014175A2 (pt) composição antibacteriana e método para tratar infecções estafilocócicas com a composição antibacteriana
MX2016007122A (es) Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos.
AR098615A1 (es) Péptido para el tratamiento de hipoglicemia severa
AR084095A1 (es) Peptidos tomm34 y vacunas que los incluyen
BR112013020195A2 (pt) composições farmacêuticas livres de citrato compreendendo anakinra
AR098616A1 (es) Péptido para el tratamiento de hipoglicemia severa
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней

Legal Events

Date Code Title Description
FB Suspension of granting procedure